Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival.
Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and
fast-growing subtype of breast cancer. This study will evaluate a new treatment using a
potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with
trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with
metastatic HER2 positive breast cancer. It is anticipated that the combination of drugs will
improve survival and have few side effects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Breast Cancer Research Foundation of Alabama Susan G. Komen Breast Cancer Foundation Tesaro, Inc. Translational Breast Cancer Research Consortium VFoundation